Rocket Lab (RKLB) has experienced significant stock price deterioration, losing 59.4% over the past six months compared to a 3.1% decline for the S&P 500, with shares closing 66.1% below their May 27 high of $150.23 as of November 19, 2026 [1]. Despite this weakness, the company has achieved notable commercial success with its next-generation Neutron rocket program, which has secured its first 16 launches with customers paying deposits before the vehicle has even launched [1]. In fiscal Q3 2026 alone, Rocket Lab signed eight new Neutron launches worth approximately $515 million—exceeding the entire $199 million in revenue generated by the Launch Services business during fiscal 2025 [1].
The Neutron program demonstrates strong pricing power, with several of the eight new launches sold at a raised base price of $70 million each, which management designated as the new baseline with expectations for further price increases [1]. Management indicated the company could have booked additional Neutron launches during the quarter but strategically held out for higher prices, suggesting confidence in demand [1]. Rocket Lab ended fiscal Q3 2026 with a substantial backlog of $3.57 billion against $882 million in trailing 12-month revenue, with launches representing approximately 52% of that backlog [1]. Management expects 32.9% of the backlog to convert to revenue within 12 months, with the remainder due further out [1].
However, the company faces near-term challenges that may explain the stock's weakness. Rocket Lab now expects Neutron's first launch in 2027 after discovering voids in the forward dome of the rocket's propellant tank, with management preferring frequent updates over specific timelines to avoid missing dates [1]. The company posted an operating loss of $244 million over the past 12 months and expects Neutron spending to remain elevated until the first launch [1]. Additionally, the stock's valuation appears stretched at 37.7 times sales compared to 3.1 times for the S&P 500, suggesting much of the growth is already priced in [1]. Over the past 12 months, RKLB returned 19.2% against 9.7% for the index, indicating recent underperformance despite the strong booking momentum [1].
CONCLUSION
Rocket Lab faces a valuation disconnect between its strong Neutron bookings and backlog ($3.57 billion) and its current stock performance, trading at a significant premium multiple (37.7x sales) while the company remains unprofitable. The key catalyst for stock recovery will be successful Neutron launches in 2027 and the company's path to profitability within six months of the first successful test flight, though near-term execution risks and high spending levels continue to pressure the stock.